HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) Spending and interest coverage
- R&D / revenue · 12 months: Value 23.01%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 4.26%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 23.01% | Research and development expense / revenue. Period ending 2026-06-30. $220.87M ÷ $959.90M × 100 ≈ 23.01% |
| Stock-based compensation / revenue · 12 months | 4.26% | Share-based compensation / revenue. Period ending 2026-06-30. $40.90M ÷ $959.90M × 100 ≈ 4.26% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 220.87M USD | Research and Development Expense |
| Revenue | 959.90M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 40.90M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 230.65M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $220.87M | $959.90M | $40.90M | $230.65M | (m) | 23.01% | 4.26% | (m) | (m) |
| 2026-03-31 | $224.44M | $899.11M | $43.02M | $189.51M | (m) | 24.96% | 4.78% | (m) | (m) |
| 2025-12-31 | $189.59M | $868.45M | $44.90M | $208.47M | (m) | 21.83% | 5.17% | (m) | (m) |
| 2025-09-30 | $174.33M | $825.94M | $44.99M | $225.64M | (m) | 21.11% | 5.45% | (m) | (m) |
| 2025-06-30 | $144.75M | $772.53M | $45.07M | $221.86M | (m) | 18.74% | 5.83% | (m) | (m) |
| 2025-03-31 | $158.18M | $744.85M | $44.71M | $195.04M | (m) | 21.24% | 6.00% | (m) | (m) |
| 2024-12-31 | $145.82M | $714.73M | $42.60M | $190.83M | (m) | 20.40% | 5.96% | (m) | (m) |
| 2024-09-30 | $141.47M | $681.88M | $41.39M | $175.29M | (m) | 20.75% | 6.07% | (m) | (m) |
| 2024-06-30 | $133.58M | $656.11M | $38.34M | $178.09M | (m) | 20.36% | 5.84% | (m) | (m) |
| 2024-03-31 | $84.96M | $617.51M | $34.90M | $203.64M | $22.56M | 13.76% | 5.65% | 9.03× | Reported |
| 2023-12-31 | $76.06M | $582.02M | $31.70M | $192.03M | $23.76M | 13.07% | 5.45% | 8.08× | Reported |
| 2023-09-30 | $55.85M | $541.92M | $30.10M | $199.45M | (m) | 10.31% | 5.55% | (m) | (m) |
| 2023-06-30 | $78.90M | $498.86M | $29.12M | $146.84M | (m) | 15.82% | 5.84% | (m) | (m) |
| 2023-03-31 | $76.60M | $471.67M | $28.75M | $133.05M | (m) | 16.24% | 6.09% | (m) | (m) |
| 2022-12-31 | $70.89M | $437.86M | $26.17M | $120.19M | (m) | 16.19% | 5.98% | (m) | (m) |
| 2022-09-30 | $68.25M | $400.76M | $23.11M | $101.20M | (m) | 17.03% | 5.77% | (m) | (m) |
| 2022-06-30 | $39.44M | $364.29M | $20.36M | $110.36M | (m) | 10.83% | 5.59% | (m) | (m) |
| 2022-03-31 | $33.27M | $331.08M | $16.99M | $100.55M | (m) | 10.05% | 5.13% | (m) | (m) |
| 2021-12-31 | $30.37M | $305.44M | $15.66M | $87.53M | (m) | 9.94% | 5.13% | (m) | (m) |
| 2021-09-30 | $30.54M | $270.51M | $14.28M | $66.66M | (m) | 11.29% | 5.28% | (m) | (m) |
| 2021-06-30 | $23.02M | $235.39M | $11.10M | $55.98M | (m) | 9.78% | 4.72% | (m) | (m) |
| 2021-03-31 | $20.70M | $199.58M | $7.63M | $41.13M | (m) | 10.37% | 3.82% | (m) | (m) |
| 2020-12-31 | $19.45M | $159.74M | $4.69M | $16.99M | (m) | 12.17% | 2.94% | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $69.59M | $6.00M | $9.91M | $-145.90M | (m) | 1160.88% | 165.29% | (m) | (m) |
| 2019-11-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-11-15 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |